| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lung Diseases | D008171 | 37 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Mycobacterium Infections | D009164 | 7 associated lipids |
| Sarcoidosis | D012507 | 13 associated lipids |
| Hepatolenticular Degeneration | D006527 | 3 associated lipids |
| Hyperglycemia | D006943 | 21 associated lipids |
| Carcinoma, Squamous Cell | D002294 | 14 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sasa H et al. | Hepatic extraction of tacrolimus in rats with experimental liver diseases. | 1998 | Biol. Pharm. Bull. | pmid:9657047 |
| Le Bihan S et al. | Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. | 1998 | Mol. Endocrinol. | pmid:9658403 |
| Fujino T et al. | The immunosuppressive compound FK506 does not affect expulsion of Echinostoma trivolvis in C3H mice. | 1998 | Parasitol. Res. | pmid:9660146 |
| McBride WJ et al. | Allogeneic fetal intestinal transplantation with FK506 immunosuppression. | 1998 | J. Pediatr. Surg. | pmid:9660232 |
| Bader G et al. | Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient. | 1998 | J. Periodontol. | pmid:9660343 |
| Tsujikawa A et al. | Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. | 1998 | Stroke | pmid:9660400 |
| Lai MM et al. | Cain, a novel physiologic protein inhibitor of calcineurin. | 1998 | J. Biol. Chem. | pmid:9660798 |
| Nagayasu T et al. | Expression of proliferating cell nuclear antigen in bronchial epithelium after lung transplantation in the rat. | 1998 | J. Heart Lung Transplant. | pmid:9662091 |
| Stockwell BR and Schreiber SL | TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. | 1998 | Chem. Biol. | pmid:9662508 |
| Kokado Y et al. | Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. | 1998 | Transpl. Int. | pmid:9664945 |
| Hauser IA and Neumayer HN | Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. | 1998 | Transpl. Int. | pmid:9664948 |
| Morris-Stiff G et al. | Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection. | 1998 | Transpl. Int. | pmid:9664949 |
| Morris-Stiff G et al. | Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. | 1998 | Transpl. Int. | pmid:9664954 |
| Kyo M et al. | Morphological findings in non-episode biopsies of kidney transplant allografts treated with FK506 or cyclosporine. | 1998 | Transpl. Int. | pmid:9664955 |
| Hernández-Herrera G et al. | Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. | 1998 | Transpl. Int. | pmid:9664956 |
| Margarit C et al. | Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. | 1998 | Transpl. Int. | pmid:9664992 |
| Pou L et al. | Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. | 1998 | Transpl. Int. | pmid:9664994 |
| Reggiani P et al. | Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. | 1998 | Transpl. Int. | pmid:9664995 |
| Jara P et al. | Tacrolimus for steroid-resistant liver rejection in children. | 1998 | Transpl. Int. | pmid:9664996 |
| Horimoto H et al. | Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. | 1998 | Transpl. Int. | pmid:9665003 |